Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoVac PEV-TBV mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- NeoVac
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
NeoVac PEV-TBV is a preclinical-stage mRNA-based vaccine candidate developed by NeoVac for the prevention of plague, a severe and potentially fatal bacterial infection caused by *Yersinia pestis*. The vaccine utilizes NeoVac's proprietary lipid nanoparticle (LNP) delivery platform to deliver mRNA encoding the F1 antigen, a major surface protein and critical virulence factor of *Y. pestis*. By expressing the F1 antigen in vivo, the vaccine is designed to stimulate a robust and protective immune response, including the production of neutralizing antibodies and T-cell activation, to provide immunity against both bubonic and pneumonic forms of the disease.
- Other names
- NeoVac PEV-TBVNeoVac plague vaccine
02
Targets
F1 capsule antigen (F1 antigen)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)F1 antigen (F1 capsular antigen)
Beyond the preview
Go deeper on NeoVac PEV-TBV mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoVac PEV-TBV mRNA vaccine.